2026 年至 2032 年深层静脉栓塞症市场（依药物类别、治疗方法、通路、最终用户和地区划分）

深层静脉栓塞症（DVT）全球市场评估 - 2026-2032

由于久坐的生活方式、肥胖、老龄以及吸烟和糖尿病等危险因素的存在，全球深层静脉栓塞症(DVT) 的盛行率正在上升。盛行率的上升使得对有效 DVT 治疗方案的需求日益增长。早期诊断和及时治疗对于预防併发症和优化患者预后至关重要，从而导致对 DVT 治疗方案的需求增加，预计 2024 年将超过 11.1 亿美元，到 2032 年将达到约 14.8 亿美元。

除此之外，我们也非常重视开发创新和改进的 DVT治疗方法。随着公司投资研发，为患者提供疗效、安全性和便利性更高的新药、医疗设备和治疗方法，该利基市场预计在 2026 年至 2032 年期间以 3.96% 的复合年增长率成长。

深层静脉栓塞症（DVT）全球市场定义/概述

深层静脉栓塞症(DVT) 是一种以深部静脉栓塞为特征的疾病，通常位于腿部。这些血块会阻塞血流并增加肺动脉栓塞的风险，这是一种危及生命的併发症。

深部静脉血栓 (DVT) 的治疗重点是防止血栓生长或破裂，并降低併发症的风险。治疗方法包括抗凝血剂、血栓溶解药物和机械血栓切除术。

持续的研究和开发正在推动 DVT 治疗的进步。新型抗凝血药物和微创手术不断涌现，为患者提供更有效、更便利的治疗方法。此外，早期诊断和预防策略的进步可能有助于改善患者的治疗效果并降低 DVT 的发生率。

老年族群中深层静脉栓塞症(DVT) 盛行率的不断上升推动了 DVT 市场的成长吗？

美国疾病管制与预防中心 (CDC) 报告称，到 2023 年，65 岁及以上成年人因 DVT 住院的人数将增加 28%。诊断工具的技术进步，特别是携带式超音波设备，提高了早期检测率。例如，2024 年 2 月，Medtronic宣布推出新的人工智慧 DVT 风险评估平台，早期检测率提高了 40%。人们对 COVID 后患者 DVT 风险因素的认识提高也促进了这一发展，美国国立卫生研究院报告称，2023 年，31% 的严重 COVID-19 患者出现了 DVT併发症。

受全球医疗保健支出增加的推动，新型抗凝血疗法和机械预防设备的采用日益增多，推动了市场的成长。根据医疗保险和医疗补助服务中心的数据，预计 2023 年 DVT 预防和治疗支出将达到 123 亿美元，年增长率为 7.2%。例如，2024年3月，强生公司的子公司Ethicon透露，其新型机械压迫装置的临床测试使术后DVT发生率降低了45%。微创手术的兴起和医院强制性的 DVT 风险评估通讯协定进一步推动了市场扩张。

全球深层静脉栓塞症(DVT) 市场面临哪些挑战，包括市场进入和治疗成本上升？

高昂的治疗费用和有限的报销政策对 DVT 市场构成了重大挑战，美国医疗保健研究与品质机构报告称，到 2023 年，每例 DVT 患者的平均住院费用将达到 14,800 美元。在保险覆盖先进治疗手段稀缺的发展中地区，经济负担尤其沉重。例如，2024 年 3 月，百时美施贵宝宣布，儘管其新型抗凝血疗法的临床结果良好，但 22% 的联合疗法患者仍被保险拒绝。患者坚持长期抗凝血治疗仍有问题，治疗开始后的前 6 个月内停药率高达 30%。

DVT 市场面临在不同医疗环境中标准化诊断方案和治疗方法的挑战，世界卫生组织报告称，到 2023 年，不同地区的 DVT 管理将出现显着差异。基层医疗医生对 DVT 早期症状和风险因素的认识不足，导致及时干预和最佳患者治疗结果的延迟。

目录

第一章全球深层静脉栓塞症市场简介

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章全球深层静脉栓塞症市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

第五章 全球深层静脉栓塞症市场（依治疗方法）

• 概述
• 血栓溶解剂
• 血液稀释剂
• 下腔静脉滤器
• 压力袜

第六章全球深层静脉栓塞症市场按分销管道

• 概述
• 零售药局
• 医院药房
• 电子商务

第七章全球深层静脉栓塞症市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他的
  • 拉丁美洲
  • 中东和非洲

8. 全球深层静脉栓塞症市场的竞争格局

• 概述
• 各公司市场排名
• 重点发展策略

第九章 公司简介

• Abbott Laboratories
• Bristol-Myers
• Squibb Company
• Pfizer
• Sanofi-Aventis
• Daiichi Sankyo Co. Ltd.
• Johnson & Johnson
• GSK
• Bayer
• Astellas Pharma

第十章 附录

• 相关调查

Global Deep Vein Thrombosis (DVT) Market Valuation - 2026-2032

The global prevalence of deep vein thrombosis (DVT) is rising, driven by factors such as sedentary lifestyles, obesity, geriatric populations, and the presence of risk factors like smoking and diabetes. This increasing incidence has led to a growing demand for effective DVT treatment options. Early diagnosis and prompt treatment are crucial for preventing complications and optimizing patient outcomes, consequently driving the demand for DVT treatment options, surpassing USD 1.11 Billion valued in 2024 to reach a valuation of around USD 1.48 Billion by 2032.

In addition to this, ongoing efforts are focused on developing innovative and improved treatments for DVT. Companies are investing in research and development to introduce novel drugs, medical devices, and therapies that offer enhanced efficacy, safety, and convenience for patients, thus enabling the niche market grow at a CAGR of 3.96% from 2026 to 2032.

Global Deep Vein Thrombosis (DVT) Market: Definition/ Overview

Deep vein thrombosis (DVT) is a medical condition characterized by the formation of a blood clot in a deep vein, typically located in the legs. This clot can obstruct blood flow and increase the risk of pulmonary embolism, a potentially life-threatening complication.

The treatment of DVT focuses on preventing the clot from growing and breaking off, as well as reducing the risk of complications. Treatment options may include anticoagulant medications, thrombolytics, and mechanical thrombectomy.

Ongoing research and development efforts are driving advancements in DVT treatment. New anticoagulant medications and minimally invasive procedures are being developed to provide more effective and convenient options for patients. Additionally, advancements in early diagnosis and prevention strategies will contribute to improved patient outcomes and reduced incidence of DVT.

How are the Rising Rising Prevalence of DVT Among Geriatric Populations Fueling the Growth of the Global Deep Vein Thrombosis (DVT) Market?

The rising prevalence of DVT, particularly among geriatric populations and post-surgical patients, is significantly expanding the market demand, with the CDC reporting a 28% increase in DVT-related hospitalizations among adults over 65 in 2023. Technological advancements in diagnostic tools, especially portable ultrasound devices, have improved early detection rates. For instance, in February 2024, Medtronic announced the launch of their new AI-powered DVT risk assessment platform, showing a 40% improvement in early detection rates. The growing awareness of DVT risk factors in post-COVID patients has also contributed to market growth, with the NIH reporting that 31% of severe COVID-19 patients developed DVT complications in 2023.

The expanding adoption of novel anticoagulant therapies and mechanical prophylaxis devices is driving market growth, supported by increasing healthcare expenditure globally. According to the Centers for Medicare & Medicaid Services, DVT prevention and treatment costs reached $12.3 billion in 2023, with a projected 7.2% annual increase. For instance, in March 2024, Johnson & Johnson's subsidiary Ethicon revealed that their new mechanical compression device achieved a 45% reduction in post-operative DVT incidents during clinical trials. The rise in minimally invasive surgical procedures and the increasing implementation of mandatory DVT risk assessment protocols in hospitals have further stimulated market expansion.

How are the Market Access and Rising Treatment Cost Hindering the Global Deep Vein Thrombosis (DVT) Market Growth?

High treatment costs and limited reimbursement policies pose significant challenges in the DVT market, with the Agency for Healthcare Research and Quality reporting an average hospitalization cost of $14,800 per DVT case in 2023. The financial burden is particularly challenging in developing regions, where insurance coverage for advanced treatments remains inadequate. For instance, in March 2024, Bristol Myers Squibb announced that despite positive clinical outcomes, insurance denials for their novel anticoagulant therapy affected 22% of prescribed patients. Patient adherence to long-term anticoagulation therapy remains problematic, with discontinuation rates reaching 30% within the first six months of treatment.

The DVT market faces challenges in standardizing diagnostic protocols and treatment approaches across different healthcare settings, with the WHO reporting significant variations in DVT management practices across regions in 2023. Limited awareness among primary care physicians about early DVT symptoms and risk factors continues to delay timely interventions and optimal patient outcomes.

Category-Wise Acumens

What are the Features Bolstering the Demand of Anticoagulants Segment?

The anticoagulants segment maintains its market dominance due to its proven efficacy and expanding therapeutic options, with the FDA reporting a 28% increase in anticoagulant prescriptions for DVT treatment in 2023 compared to the previous year. Direct oral anticoagulants (DOACs) have revolutionized DVT management by offering convenient dosing regimens and reduced monitoring requirements. The development of reversal agents for anticoagulants has enhanced their safety profile, making them the preferred choice among healthcare providers and patients alike.

The market growth is further propelled by the introduction of biosimilars and generic alternatives, making treatment more accessible and cost-effective, with the U.S. Department of Health reporting a 31% reduction in average treatment costs for DVT patients using generic anticoagulants in 2023. Recent advancements in drug delivery systems and personalized dosing approaches have improved patient compliance and treatment outcomes. The expansion of indication ranges for existing anticoagulants and increased insurance coverage have significantly contributed to market penetration across different patient populations.

What Factors are Responsible to Project the Market Growth of Surgical Segment?

The surgical segment is dominating the global deep vein thrombosis (DVT) market, driven by the increasing adoption of minimally invasive thrombectomy procedures, with the FDA reporting a 28% year-over-year increase in approved surgical devices for DVT in 2023. The segment's growth is further propelled by technological advancements in surgical techniques and equipment, particularly in mechanical thrombectomy devices. The rising prevalence of post-operative DVT cases, especially in orthopedic and bariatric surgeries, has created a substantial demand for surgical interventions.

Advanced surgical techniques have shown superior outcomes in treating extensive DVT cases, with the American College of Surgeons reporting a 32% reduction in post-thrombotic syndrome when surgical interventions are used as primary treatment in 2023. The integration of robotic-assisted surgical systems and image-guided procedures has improved precision and reduced recovery times, making surgical options more appealing to both healthcare providers and patients.

Country/Region-wise Acumens

How are the Advanced Healthcare Infrastructure and Market Players Maintaining the

North American Deep Vein Thrombosis (DVT) Dominance?

The North American DVT treatment market is maintaining its global dominance, largely driven by the United States, where according to the CDC's 2023 data, between 60,000-100,000 Americans die annually from DVT/PE (Pulmonary Embolism). This robust market position is further strengthened by the region's advanced healthcare infrastructure and the presence of key market players, exemplified by Janssen Pharmaceuticals' March 2024 announcement of expanding their XARELTO(R) (rivaroxaban) manufacturing facility in Puerto Rico to meet growing demand.

The market's leadership is also attributed to high disease awareness and extensive insurance coverage, with Medicare reporting in December 2023 that DVT treatments, including newer direct oral anticoagulants (DOACs), are covered under Part D for over 65 million beneficiaries. This regional dominance was further solidified when Bristol Myers Squibb announced in January 2024 their collaboration with major U.S. healthcare systems to implement AI-driven DVT risk assessment protocols, potentially revolutionizing early detection and treatment approaches.

How are the Expanding Access to DVT Treatments Fueling the Demand of Deep Vein Thrombosis (DVT) in Asia Pacific?

The Asia Pacific region is experiencing significant growth in the global Deep Vein Thrombosis (DVT) treatment market. This growth is largely driven by rising incidences of DVT linked to sedentary lifestyles, obesity, and an geriatric population. Notably, government initiatives such as India's National Health Mission, which received about USD 5 million in funding for 2021-2022 to improve healthcare services, are enhancing access to DVT treatments.

Recent developments in the market further highlight this trend. For instance, in June 2021, the FDA approved Pradaxa (dabigatran etexilate) for pediatric patients aged 3 months to 12 years, marking a significant advancement in DVT treatment options. Additionally, major pharmaceutical companies like Pfizer and Bristol-Myers Squibb are increasing their investments in research and development, aiming to innovate and expand their product offerings in response to the growing demand for effective DVT therapies

Competitive Landscape

The global deep vein thrombosis (DVT) market is a dynamic and competitive landscape, with a mix of established players and emerging challengers vying for market share. These players are actively working to strengthen their presence by implementing strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are dedicated to continuously improving their product line to meet the needs of a wide range of customers in different regions.

Some of the key players operating in the global deep vein thrombosis (DVT) market include:

Aspen Holdings

Novartis AG

Mylan N.V.

Momenta Pharmaceuticals, Inc.

Hikma Pharmaceuticals PLC

Laboratorios FarmaceuticosRovi, S.A.

GL Pharma

Cobapharma

BoehringerIngelheim GmbH

Glenmark Pharmaceuticals Inc.

Latest Developments

In February 2024, for patients with deep vein thrombosis, Bayer initiated a Phase II clinical trial (SIRIUS study) for BAY3018250, a first-in-class anti-alpha2 antiplasmin (anti-a2ap) antibody. The plasmin inhibitor a2ap, which is essential for blood coagulation and breaks up clots in situ, is inhibited by BAY3018250.

In November 2023, during a Late-Breaking session of the American Heart Association (AHA) meeting, Anthos Therapeutics, Inc. reported a highly significant reduction in bleeding events across all primary and secondary endpoints by abelacimab when compared to a standard-of-care direct-oral anticoagulant (DOAC)

In June 2021, Pradaxa (dabigatran etexilate), the first oral blood thinner approved by the FDA, is used to treat DVT in children aged three months to twelve years.

Global Deep Vein Thrombosis (DVT) Market, By Category

• Drugs Class:
• Anticoagulants
• Heparin
• Others
• Treatment:
• Anticoagulants
• Heparin
• Others
• Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• End-User:
• Hospitals
• Homecare
• Specialty Clinics
• Others
• Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DEEP VEIN THROMBOSIS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL DEEP VEIN THROMBOSIS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL DEEP VEIN THROMBOSIS MARKET, BY TREATMENT

• 5.1 Overview
• 5.2 Clot Busters
• 5.3 Blood Thinners
• 5.4 Inferior Vena Cava Filters
• 5.5 Compression Stocking

6 GLOBAL DEEP VEIN THROMBOSIS MARKET, BY DISTRIBUTION CHANNEL

• 6.1 Overview
• 6.2 Retail Pharmacy
• 6.3 Hospital Pharmacy
• 6.4 E-Commerce

7 GLOBAL DEEP VEIN THROMBOSIS MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL DEEP VEIN THROMBOSIS MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Abbott Laboratories
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Bristol-Myers
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Squibb Company
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Pfizer
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Sanofi-Aventis
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Daiichi Sankyo Co. Ltd.
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Johnson & Johnson
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 GSK
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Bayer
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Astellas Pharma
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research